Kodai Capital Management LP Makes New Investment in Kiniksa Pharmaceuticals International, plc $KNSA

Key Points

• Kodai Capital Management LP has acquired a new position in Kiniksa Pharmaceuticals, purchasing 185,364 shares valued at approximately $4.12 million, bringing its ownership to about 0.25% of the company.
• Insiders have been actively selling shares, with notable transactions including John F. Paolini and Thomas Malley selling a combined over 100,000 shares in August, indicating significant decreases in their ownership stakes.
• Kiniksa Pharmaceuticals reported a net margin of 0.90% and exceeded revenue expectations with $156.80 million for the quarter, as analysts anticipate the company will post a EPS of -0.55 for the current fiscal year.

Kodai Capital Management LP acquired a new stake in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 185,364 shares of the company's stock, valued at approximately $4,117,000. Kodai Capital Management LP owned 0.25% of Kiniksa Pharmaceuticals International at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the stock. GAMMA Investing LLC grew its position in shares of Kiniksa Pharmaceuticals International by 84.8% in the 1st quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock worth $27,000 after buying an additional 568 shares during the period. US Bancorp DE purchased a new stake in shares of Kiniksa Pharmaceuticals International in the 1st quarter worth about $33,000. Asset Management One Co. Ltd. purchased a new stake in shares of Kiniksa Pharmaceuticals International in the 1st quarter worth about $41,000. Wealthquest Corp purchased a new stake in shares of Kiniksa Pharmaceuticals International in the 1st quarter worth about $42,000. Finally, Lazard Asset Management LLC purchased a new stake in shares of Kiniksa Pharmaceuticals International in the 4th quarter worth about $61,000. 53.95% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Kiniksa Pharmaceuticals International news, insider John F. Paolini sold 29,325 shares of the stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $32.55, for a total value of $954,528.75. Following the transaction, the insider directly owned 57,403 shares in the company, valued at approximately $1,868,467.65. This trade represents a 33.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Thomas Malley sold 78,233 shares of the firm's stock in a transaction on Thursday, August 14th. The shares were sold at an average price of $33.09, for a total transaction of $2,588,729.97. Following the sale, the director owned 12,546 shares in the company, valued at $415,147.14. The trade was a 86.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 558,403 shares of company stock valued at $18,078,671 in the last 90 days. 53.48% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of research firms have recently weighed in on KNSA. Wall Street Zen downgraded shares of Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 30th. Jefferies Financial Group increased their price objective on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a "buy" rating in a research report on Tuesday, July 29th. Wedbush reissued an "outperform" rating and set a $36.00 price objective on shares of Kiniksa Pharmaceuticals International in a research report on Monday, July 21st. Finally, Wells Fargo & Company increased their price objective on shares of Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the company an "overweight" rating in a research report on Wednesday, July 9th. Six equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $41.17.

Kiniksa Pharmaceuticals International Stock Down 0.3%

KNSA traded down $0.11 during midday trading on Thursday, hitting $35.38. 131,524 shares of the company traded hands, compared to its average volume of 671,741. The firm has a market capitalization of $2.62 billion, a PE ratio of 884.60 and a beta of 0.20. The company's 50-day moving average is $30.65 and its 200 day moving average is $26.27. Kiniksa Pharmaceuticals International, plc has a 52 week low of $17.82 and a 52 week high of $35.59.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last posted its earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.18 by $0.05. The business had revenue of $156.80 million for the quarter, compared to analysts' expectations of $145.21 million. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current fiscal year.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.